BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 05, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/2 cls
Avanir (AVNR) Punk Matthew Kaplan Price target Sell -33% $1.43
Kaplan lowered his target to $1.25 from $2 based on AVNR's plan to address FDA safety concerns by running an additional Phase III trial of Zenvia to treat involuntary emotional expression disorder (IEED) using a lower dose of quinidine. Kaplan expects the trial to take at least 2 years to complete, representing a 3-year delay to approval.
Cytogen (CYTO) JMP Securities Charles Duncan Discontinued Market outperform 1% $2.41
The firm dropped coverage due to lack of clinical catalysts.
Dynavax (DVAX) JMP Securities Charles Duncan Downgrade Market perform...

Read the full 681 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >